Sarepta Therapeutics Stock Plummets Over 40% On Second Fatal Case Linked To Its Gene Therapy

Why did Metaplanet's Bitcoin holdings surge? How is the Israel-Iran conflict impacting oil prices? What caused Uber and unions to settle driver wage dispute? Why is Trump launching a mobile phone company? How did Trump's approval affect U.S. Steel's stock? What explains AMD's recent stock rally? Why are WhatsApp ads now rolling out?

Sarepta Therapeutics Stock Plummets Over 40% On Second Fatal Case Linked To Its Gene Therapy

benzinga.com/news/fda/25/06/45945282/sarepta-therapeutics-stock-plummets-over-40-on-second-fatal-case-linked-to-its-gene-therapy

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stock experienced a steep decline of approximately 40% in premarket trading on Monday following a sobering safety update for its Duchenne muscular dystrophy (DMD) gene therapy, Elevidys.
What Happened: On Sunday, Sarepta provided a safety update…

This story appeared on benzinga.com, 2025-06-16 10:50:28.